Intravesical Therapy

  • Jennifer J. Ahn
  • James M. McKiernanEmail author


Intravesical therapy is an essential component in the treatment and prevention of non-muscle invasive bladder cancer. The bladder has specific properties which are amenable to local drug administration, enabling therapeutic effect while minimizing systemic exposure. The two primary forms of intravesical therapy are chemotherapy and immunotherapy. Chemotherapy can be administered perioperatively, in the adjuvant setting, and with maintenance, reducing recurrence rates. Immunotherapy primarily relies upon BCG, which reduces recurrence rates as well as progression, though with a possible increased side effect profile. Optimizing efficacy and enhancing drug delivery are current foci of active research, employing assistive technologies, new drug formulations, and host factors involved in the immune response. This chapter provides an overview of risks, benefits, and indications for existing intravesical agents.


Non-muscle invasive bladder cancer Intravesical therapy Immunotherapy Bacillus Calmette-Guerin Optimization Side effects Intravesical chemotherapy 



Funding sources:

Dr. McKiernan: Celgene, Prostate Cancer Foundation.

Dr. Ahn: none.


  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. Epub 2013/01/22.PubMedCrossRefGoogle Scholar
  2. 2.
    Logan C, Brown M, Hayne D. Intravesical therapies for bladder cancer—indications and limitations. BJU Int. 2012;110 Suppl 4:12–21. Epub 2012/12/05.PubMedCrossRefGoogle Scholar
  3. 3.
    GuhaSarkar S, Banerjee R. Intravesical drug delivery: challenges, current status, opportunities and novel strategies. J Control Release. 2010;148(2):147–59. Epub 2010/09/14.PubMedCrossRefGoogle Scholar
  4. 4.
    Mishina T, Watanabe H, Kobayashi T, Maegawa M, Nakao M, Nakagawa S. Absorption of anticancer drugs through bladder epithelium. Urology. 1986;27(2):148–57. Epub 1986/02/01.PubMedCrossRefGoogle Scholar
  5. 5.
    Shen Z, Shen T, Wientjes MG, O'Donnell MA, Au JL. Intravesical treatments of bladder cancer: review. Pharm Res. 2008;25(7):1500–10. Epub 2008/03/29.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Au JL, Badalament RA, Wientjes MG, Young DC, Warner JA, Venema PL, et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst. 2001;93(8):597–604. Epub 2001/04/20.PubMedCrossRefGoogle Scholar
  7. 7.
    Nargund VH, Tanabalan CK, Kabir MN. Management of non-muscle-invasive (superficial) bladder cancer. Semin Oncol. 2012;39(5):559–72. Epub 2012/10/09.PubMedCrossRefGoogle Scholar
  8. 8.
    Bateman JC. Chemotherapy of solid tumors with triethylene thiophosphoramide. N Engl J Med. 1955;252(21):879–87. Epub 1955/05/26.PubMedCrossRefGoogle Scholar
  9. 9.
    Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Acta Urol Esp. 2012;36(7):389–402. Epub 2012/03/06.Google Scholar
  10. 10.
    Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007;178(6):2314–30. Epub 2007/11/13.PubMedCrossRefGoogle Scholar
  11. 11.
    Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004;171(6 Pt 1):2186–90. quiz 435. Epub 2004/05/06.PubMedCrossRefGoogle Scholar
  12. 12.
    Chamie K, Saigal CS, Lai J, Hanley JM, Setodji CM, Konety BR, et al. Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer. 2011;117(23):5392–401. Epub 2011/07/23.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Pawinski A, Sylvester R, Kurth KH, Bouffioux C, van der Meijden A, Parmar MK, et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol. 1996;156(6):1934–40. Discussion 40–1. Epub 1996/12/01.PubMedCrossRefGoogle Scholar
  14. 14.
    Tolley DA, Parmar MK, Grigor KM, Lallemand G, Benyon LL, Fellows J, et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol. 1996;155(4):1233–8. Epub 1996/04/01.PubMedCrossRefGoogle Scholar
  15. 15.
    Kaasinen E, Rintala E, Hellstrom P, Viitanen J, Juusela H, Rajala P, et al. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol. 2002;42(2):167–74. Epub 2002/08/06.PubMedCrossRefGoogle Scholar
  16. 16.
    Shelley MD, Mason MD, Kynaston H. Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treat Rev. 2010;36(3):195–205. Epub 2010/01/19.PubMedCrossRefGoogle Scholar
  17. 17.
    Huncharek M, Kupelnick B. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation. Am J Clin Oncol. 2003;26(4):402–7. Epub 2003/08/07.PubMedGoogle Scholar
  18. 18.
    Huncharek M, Kupelnick B. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy. Am J Clin Oncol. 2004;27(5):522–8. Epub 2004/12/15.PubMedCrossRefGoogle Scholar
  19. 19.
    Bohle A, Bock PR. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology. 2004;63(4):682–6. Discussion 6–7. Epub 2004/04/10.PubMedCrossRefGoogle Scholar
  20. 20.
    Gardmark T, Jahnson S, Wahlquist R, Wijkstrom H, Malmstrom PU. Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guerin in patients with high-risk bladder cancer. BJU Int. 2007;99(4):817–20. Epub 2007/01/25.PubMedCrossRefGoogle Scholar
  21. 21.
    Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003;169(1):90–5. Epub 2002/12/13.PubMedCrossRefGoogle Scholar
  22. 22.
    Lammers RJ, Witjes JA, Inman BA, Leibovitch I, Laufer M, Nativ O, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol. 2011;60(1):81–93. Epub 2011/05/03.PubMedCrossRefGoogle Scholar
  23. 23.
    Colombo R, Salonia A, Leib Z, Pavone-Macaluso M, Engelstein D. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int. 2011;107(6):912–8. Epub 2010/10/30.PubMedCrossRefGoogle Scholar
  24. 24.
    Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Navarra P, Massoud R, et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol. 2003;170(3):777–82. Epub 2003/08/13.PubMedCrossRefGoogle Scholar
  25. 25.
    Di Stasi SM, Valenti M, Verri C, Liberati E, Giurioli A, Leprini G, et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol. 2011;12(9):871–9. Epub 2011/08/13.PubMedCrossRefGoogle Scholar
  26. 26.
    Di Stasi SM, Giannantoni A, Giurioli A, Valenti M, Zampa G, Storti L, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 2006;7(1):43–51. Epub 2006/01/04.PubMedCrossRefGoogle Scholar
  27. 27.
    The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial. Medical Research Council Working Party on Urological Cancer, Subgroup on Superficial Bladder Cancer. Br J Urol. 1994;73(6):632–8. Epub 1994/06/01.Google Scholar
  28. 28.
    Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010;57(5):766–73.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Gudjonsson S, Adell L, Merdasa F, Olsson R, Larsson B, Davidsson T, et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol. 2009;55(4):773–80. Epub 2009/01/21.PubMedCrossRefGoogle Scholar
  30. 30.
    Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol. 2000;163(3):761–7. Epub 2000/02/25.PubMedCrossRefGoogle Scholar
  31. 31.
    Dalbagni G, Russo P, Sheinfeld J, Mazumdar M, Tong W, Rabbani F, et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol. 2002;20(15):3193–8. Epub 2002/08/01.PubMedCrossRefGoogle Scholar
  32. 32.
    Bohle A, Leyh H, Frei C, Kuhn M, Tschada R, Pottek T, et al. Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study. Eur Urol. 2009;56(3):495–503. Epub 2009/06/30.PubMedCrossRefGoogle Scholar
  33. 33.
    Shelley MD, Jones G, Cleves A, Wilt TJ, Mason MD, Kynaston HG. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review. BJU Int. 2012;109(4):496–505. Epub 2012/02/09.PubMedCrossRefGoogle Scholar
  34. 34.
    Addeo R, Caraglia M, Bellini S, Abbruzzese A, Vincenzi B, Montella L, et al. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol. 2010;28(4):543–8. Epub 2009/10/21.PubMedCrossRefGoogle Scholar
  35. 35.
    Di Lorenzo G, Perdona S, Damiano R, Faiella A, Cantiello F, Pignata S, et al. Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer. 2010;116(8):1893–900. Epub 2010/02/18.PubMedCrossRefGoogle Scholar
  36. 36.
    Skinner EC, Goldman B, Sakr WA, Petrylak DP, Lenz HJ, Lee CT, et al. SWOG S0353: phase II trial of intravesical gemcitabine in patients with non-muscle invasive bladder cancer who recurred following at least two prior courses of intravesical BCG. J Urol. 2013;190(4):1200–4. Epub 2013/04/20.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    McKiernan JM, Masson P, Murphy AM, Goetzl M, Olsson CA, Petrylak DP, et al. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol. 2006;24(19):3075–80. Epub 2006/07/01.PubMedCrossRefGoogle Scholar
  38. 38.
    Bassi PF, Volpe A, D’Agostino D, Palermo G, Renier D, Franchini S, et al. Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder: results of a phase I study. J Urol. 2011;185(2):445–9. Epub 2010/12/21.PubMedCrossRefGoogle Scholar
  39. 39.
    McKiernan JM, Barlow LJ, Laudano MA, Mann MJ, Petrylak DP, Benson MC. A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guerin refractory nonmuscle invasive bladder cancer. J Urol. 2011;186(2):448–51. Epub 2011/06/18.PubMedCrossRefGoogle Scholar
  40. 40.
    Hendricksen K, Cornel EB, de Reijke TM, Arentsen HC, Chawla S, Witjes JA. Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer. J Urol. 2012;187(4):1195–9. Epub 2012/02/18.PubMedCrossRefGoogle Scholar
  41. 41.
    Lightfoot AJ, Breyer BN, Rosevear HM, Erickson BA, Konety BR, O’Donnell MA. Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer. Urol Oncol. 2013;32(1):e15–9. Epub 2013/03/21.PubMedGoogle Scholar
  42. 42.
    Chen CH, Yang HJ, Shun CT, Huang CY, Huang KH, Yu HJ, et al. A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer. Urol Oncol. 2012;30(4):421–7. Epub 2010/09/28.PubMedCrossRefGoogle Scholar
  43. 43.
    Burke JM, Lamm DL, Meng MV, Nemunaitis JJ, Stephenson JJ, Arseneau JC, et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol. 2012;188(6):2391–7. Epub 2012/10/24.PubMedCrossRefGoogle Scholar
  44. 44.
    Kowalski M, Guindon J, Brazas L, Moore C, Entwistle J, Cizeau J, et al. A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guerin. J Urol. 2012;188(5):1712–8. Epub 2012/09/25.PubMedCrossRefGoogle Scholar
  45. 45.
    Giannantoni A, Di Stasi SM, Chancellor MB, Costantini E, Porena M. New frontiers in intravesical therapies and drug delivery. Eur Urol. 2006;50(6):1183–93. Discussion 93. Epub 2006/09/12.PubMedCrossRefGoogle Scholar
  46. 46.
    Pearl R. Cancer and tuberculosis. Am J Hygiene. 1929;9:97–159.Google Scholar
  47. 47.
    Old LJ, Clarke DA, Benacerraf B. Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature. 1959;184 Suppl 5:291–2. Epub 1959/07/25.PubMedCrossRefGoogle Scholar
  48. 48.
    Zbar B, Bernstein ID, Rapp HJ. Suppression of tumor growth at the site of infection with living Bacillus Calmette-Guerin. J Natl Cancer Instit. 1971;46(4):831–9. Epub 1971/04/01.Google Scholar
  49. 49.
    deKernion JB, Golub SH, Gupta RK, Silverstein M, Morton DL. Successful transurethral intralesional BCG therapy of a bladder melanoma. Cancer. 1975;36(5):1662–7. Epub 1975/11/01.PubMedCrossRefGoogle Scholar
  50. 50.
    Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180–3. Epub 1976/08/01.PubMedGoogle Scholar
  51. 51.
    Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol. 1980;124(1):38–40. Epub 1980/07/01.PubMedGoogle Scholar
  52. 52.
    Kawai K, Miyazaki J, Joraku A, Nishiyama H, Akaza H. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. Cancer Sci. 2013;104(1):22–7. Epub 2012/11/28.PubMedCrossRefGoogle Scholar
  53. 53.
    Askeland EJ, Newton MR, O'Donnell MA, Luo Y. Bladder cancer immunotherapy: BCG and beyond. Adv Urol. 2012;2012:181987. Epub 2012/07/11.PubMedCentralPubMedCrossRefGoogle Scholar
  54. 54.
    Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L, et al. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. J Urol. 2002;167(1):364–7. Epub 2001/12/18.PubMedCrossRefGoogle Scholar
  55. 55.
    Lamm DL, Riggs DR, Shriver JS, vanGilder PF, Rach RF, DeHaven JI. Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol. 1994;151(1):21–6. Epub 1994/01/01.PubMedGoogle Scholar
  56. 56.
    Luftenegger W, Ackermann DK, Futterlieb A, Kraft R, Minder CE, Nadelhaft P, et al. Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors. J Urol. 1996;155(2):483–7. Epub 1996/02/01.PubMedCrossRefGoogle Scholar
  57. 57.
    Shah JB, Kamat AM. Strategies for optimizing bacillus Calmette-Guerin. Urol Clin N Am. 2013;40(2):211–8. Epub 2013/04/02.CrossRefGoogle Scholar
  58. 58.
    Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013;63(3):462–72. Epub 2012/11/13.PubMedCrossRefGoogle Scholar
  59. 59.
    Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124–9. Epub 2000/03/29.PubMedCrossRefGoogle Scholar
  60. 60.
    Gontero P, Bohle A, Malmstrom PU, O’Donnell MA, Oderda M, Sylvester R, et al. The role of bacillus Calmette-Guerin in the treatment of non-muscle-invasive bladder cancer. Eur Urol. 2010;57(3):410–29. Epub 2009/12/09.PubMedCrossRefGoogle Scholar
  61. 61.
    Colombel M, Saint F, Chopin D, Malavaud B, Nicolas L, Rischmann P. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol. 2006;176(3):935–9. Epub 2006/08/08.PubMedCrossRefGoogle Scholar
  62. 62.
    Damiano R, De Sio M, Quarto G, Di Lorenzo G, Perdona S, Palumbo IM, et al. Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Guerin-induced toxicity? BJU Int. 2009;104(5):633–9. Epub 2009/03/21.PubMedCrossRefGoogle Scholar
  63. 63.
    Jarvinen R, Kaasinen E, Sankila A, Rintala E, FinnBladder G. Long-term efficacy of maintenance bacillus Calmette-Guerin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol. 2009;56(2):260–5. Epub 2009/04/28.PubMedCrossRefGoogle Scholar
  64. 64.
    Sylvester RJ, van der MA, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964–70. Epub 2002/10/24.PubMedCrossRefGoogle Scholar
  65. 65.
    Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol. 2005;174(1):86–91. Discussion-2. Epub 2005/06/11.PubMedCrossRefGoogle Scholar
  66. 66.
    Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E, Rodriguez RH, Gomez JM, Martin MG, et al. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol. 2005;174(4 Pt 1):1242–7. Epub 2005/09/08.PubMedCrossRefGoogle Scholar
  67. 67.
    Fernandez-Gomez J, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M, Hernandez R, et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials. Eur Urol. 2008;53(5):992–1001. Epub 2007/10/24.PubMedCrossRefGoogle Scholar
  68. 68.
    Herr HW. Age and outcome of superficial bladder cancer treated with bacille Calmette-Guerin therapy. Urology. 2007;70(1):65–8. Epub 2007/07/28.PubMedCrossRefGoogle Scholar
  69. 69.
    Joudi FN, Smith BJ, O’Donnell MA, Konety BR. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol. 2006;175(5):1634–9. Discussion 9–40. Epub 2006/04/08.PubMedCrossRefGoogle Scholar
  70. 70.
    Nepple KG, Lightfoot AJ, Rosevear HM, O'Donnell MA, Lamm DL. Bladder Cancer Genitourinary Oncology Study G. Bacillus Calmette-Guerin with or without interferon alpha-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J Urol. 2010;184(5):1915–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Saint F, Salomon L, Quintela R, Cicco A, Hoznek A, Abbou CC, et al. Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guerin (BCG) immunotherapy exist? Analysis of a quarter century of literature. Eur Urol. 2003;43(4):351–60.PubMedCrossRefGoogle Scholar
  72. 72.
    Saint F, Patard JJ, Irani J, Salomon L, Hoznek A, Legrand P, et al. Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer. Urology. 2001;57(4):617–21. Discussion 21–2. Epub 2001/04/18.PubMedCrossRefGoogle Scholar
  73. 73.
    Herr HW, Dalbagni G. Intravesical bacille Calmette-Guerin (BCG) in immunologically compromised patients with bladder cancer. BJU Int. 2013;111(6): 984–7. Epub 2013/01/29.PubMedCrossRefGoogle Scholar
  74. 74.
    Rentsch CA, Biot C, Gsponer JR, Bachmann A, Albert ML, Breban R. BCG-mediated bladder cancer immunotherapy: identifying determinants of treatment response using a calibrated mathematical model. PloS one. 2013;8(2):e56327. Epub 2013/03/02.PubMedCentralPubMedCrossRefGoogle Scholar
  75. 75.
    Morales A, Phadke K, Steinhoff G. Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed. J Urol. 2009;181(3):1040–5. Epub 2009/01/20.PubMedCrossRefGoogle Scholar
  76. 76.
    Glashan RW. A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. J Urol. 1990;144(3):658–61. Epub 1990/09/01.PubMedGoogle Scholar
  77. 77.
    Belldegrun AS, Franklin JR, O’Donnell MA, Gomella LG, Klein E, Neri R, et al. Superficial bladder cancer: the role of interferon-alpha. J Urol. 1998;159(6):1793–801. Epub 1998/05/23.PubMedCrossRefGoogle Scholar
  78. 78.
    Joudi FN, Smith BJ, O’Donnell MA, National BCGIPIG. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urologic oncology. 2006;24(4):344–8. Epub 2006/07/05.PubMedCrossRefGoogle Scholar
  79. 79.
    O’Donnell MA, Lilli K, Leopold C. National Bacillus Calmette-Guerin/Interferon Phase 2 Investigator G. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol. 2004;172(3):888–93.PubMedCrossRefGoogle Scholar
  80. 80.
    Nagabhushan TL, Maneval DC, Benedict WF, Wen SF, Ihnat PM, Engler H, et al. Enhancement of intravesical delivery with Syn3 potentiates interferon-alpha2b gene therapy for superficial bladder cancer. Cytokine Growth Factor Rev. 2007;18(5–6):389–94. Epub 2007/08/19.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of Urology, New York-Presbyterian HospitalColumbia UniversityNew YorkUSA
  2. 2.Department of UrologyColumbia University Medical Center, Herbert Irving PavilionNew YorkUSA

Personalised recommendations